口服抗凝剂
医学
药品
抗凝剂
重症监护医学
药理学
内科学
华法林
心房颤动
作者
Jean Escal,Géraldine Poenou,Xavier Delavenne,Souad Bezzeghoud,Valentine Mismetti,Marc Humbert,Marc Humbert,Laurent Bertoletti
标识
DOI:10.1016/j.blre.2024.101240
摘要
The use of oral anticoagulants in the management of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) presents distinct therapeutic challenges and benefits. In PAH, the benefits of oral anticoagulation are uncertain, with studies yielding mixed results on their efficacy and safety. Conversely, oral anticoagulants are a cornerstone in the treatment of CTEPH, where their use is consistently recommended to prevent recurrent thromboembolic events. The choice between vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs) remains a significant clinical question, as each type presents advantages and potential drawbacks. Furthermore, drug-drug interactions (DDIs) with concomitant PAH and CTEPH treatments complicate anticoagulant management, necessitating careful consideration of individual patient regimens. This review examines the current evidence on oral anticoagulant use in PAH and CTEPH and discusses the implications of DDIs within a context of multi-drug treatments, including targeted drugs in PAH.
科研通智能强力驱动
Strongly Powered by AbleSci AI